An observational study in Familial Hypertriglyceridemia, sponsored by Region Stockholm. Active, not recruiting. Per ClinicalTrials.gov, last updated 2023-10-27.
Sponsored by Region Stockholm · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The STRIREG study is a retrospective longitudinal general population-based register study including all individuals who had had at least one plasma Tg measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Region Stockholm (population 2.41 million 2021). The exclusion criteria were a lack of a unique Swedish personal identification number (PIN). The index population consisted of 1,460,184 individuals between the age 0 and 107 years. The index population was extended to form the complete cohort (n=3,607,819) by associating the parents and the siblings (n=2,147,635) to the indexes by interlinkage of personal identification numbers via the Multi-Generation register (see below).
The study baseline for the index population was defined as the date for participant's first Tg measurement.
Hypertriglyceridemia (hTG) is associated with atherosclerotic cardiovascular disease, pancreatitis, and non-alcoholic fatty liver disease in large population-based studies. Less is known about the impact on hereditary hTG and cardiometabolic disease status for the development of hTG and its associated cardiometabolic outcomes. hTG remains a target for lipid lowering therapies and with new pharmacological interventions being developed, there is a need to identify patients that will benefit most from treatment with these new medicines.
The population-based observational Stockholm hyperTRIglyceridemia REGister (STRIREG) study include 1,460,184 index individuals that have measured plasma triglycerides in the clinical routine in Region Stockholm, Sweden, between 1st January 2000 and 31st December 2021. The laboratory measurements also included basic haematology, blood lipid panel, liver function tests and HbA1c. Using the Swedish Multi-Generation register, 2,147,635 parents and siblings to the indexes were identified to form the complete study cohort. Laboratory data from participants were combined with data from several national registers that provided information on cause of death, medical diagnoses, dispensed medicines, and socioeconomic factors including country of birth, education level and marital status.
The multigenerational longitudinal STRIREG cohort provides a unique opportunity to investigate different aspects of familial hTG as well as heredity for other metabolic diseases. Important outcome measures include mortality, cardiovascular mortality, major cardiovascular events, development of incident diabetes, and non-alcoholic fatty liver disease. The STRIREG study will provide a deeper understanding of the impact of heredity on hTG and associated cardiometabolic complications.
Region Stockholm is the lead sponsor of 122 studies on the registry; 70 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Populationbased cohort originating from Stockholm County. with all individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County Sweden. The first degree relatives are parents and siblings to the index patients identified through the Swedish Multi-Generation Register.
Inclusion Criteria: All individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County Sweden.
Exclusion Criteria: No Swedish social security number.
All individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County in Sweden.
Other: Heredity for cardiovascular disease · Other: Heredity for pancreatitis · Other: Heredity for type 2 diabetes · Other: Heredity for hypertriglyceridemia
Parents and the siblings to the index patients by interlinkage of personal identification numbers via the Swedish Multi-Generation register.
First degree relatives with a diagnosis of Cardiovascular disease.
First degree relatives with a diagnosis of pancreatitis.
First degree relatives with a diagnosis of type 2 diabetes.
First degree relatives with hypertriglyceridemia
Mortality
All cause mortality
Time frame: Jan 1 2000 to Dec 31 2021
Cardiovascular mortality
Cardiovascular mortality
Time frame: Jan 1 2000 to Dec 31 2021
Pancreatitis
Pancreatitis
Time frame: Jan 1 2000 to Dec 31 2021
Major cardiovascular event (MACE)
Major cardiovascular event (MACE)
Time frame: Jan 1 2000 to Dec 31 2021
Myocardial infarction
Myocardial infarction
Time frame: Jan 1 2000 to Dec 31 2021
Stroke
Stroke
Time frame: Jan 1 2000 to Dec 31 2021
Peripheral artery disease
Peripheral artery disease
Time frame: Jan 1 2000 to Dec 31 2021
Type 2 diabetes
Type 2 diabetes
Time frame: Jan 1 2000 to Dec 31 2021
Cardiac revascularization
Cardiac revascularization
Time frame: Jan 1 2000 to Dec 31 2021
Non alcoholic fatty liver disease
Non alcoholic fatty liver disease
Time frame: Jan 1 2000 to Dec 31 2021
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2000 to primary completion in Dec 2021, 263 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type IV